650 related articles for article (PubMed ID: 33400075)
21. Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds.
Samatov TR; Tonevitsky AG; Schumacher U
Mol Cancer; 2013 Sep; 12(1):107. PubMed ID: 24053443
[TBL] [Abstract][Full Text] [Related]
22. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
23. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing.
Xu Y; Gao XD; Lee JH; Huang H; Tan H; Ahn J; Reinke LM; Peter ME; Feng Y; Gius D; Siziopikou KP; Peng J; Xiao X; Cheng C
Genes Dev; 2014 Jun; 28(11):1191-203. PubMed ID: 24840202
[TBL] [Abstract][Full Text] [Related]
24. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
25. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression.
Brown RL; Reinke LM; Damerow MS; Perez D; Chodosh LA; Yang J; Cheng C
J Clin Invest; 2011 Mar; 121(3):1064-74. PubMed ID: 21393860
[TBL] [Abstract][Full Text] [Related]
26. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
27. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.
Zhang FL; Cao JL; Xie HY; Sun R; Yang LF; Shao ZM; Li DQ
Cancer Res; 2018 Oct; 78(20):5780-5792. PubMed ID: 30093560
[TBL] [Abstract][Full Text] [Related]
28. Predictive Value of CD44 in Muscle-Invasive Bladder Cancer and Its Relationship with IL-6 Signaling.
Wu CT; Lin WY; Chen WC; Chen MF
Ann Surg Oncol; 2018 Nov; 25(12):3518-3526. PubMed ID: 30128900
[TBL] [Abstract][Full Text] [Related]
29. CD44: A Multifunctional Mediator of Cancer Progression.
Hassn Mesrati M; Syafruddin SE; Mohtar MA; Syahir A
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944493
[TBL] [Abstract][Full Text] [Related]
30. Making alternative splicing decisions during epithelial-to-mesenchymal transition (EMT).
Biamonti G; Bonomi S; Gallo S; Ghigna C
Cell Mol Life Sci; 2012 Aug; 69(15):2515-26. PubMed ID: 22349259
[TBL] [Abstract][Full Text] [Related]
31. Cancer stem cell epigenetics and chemoresistance.
Crea F; Danesi R; Farrar WL
Epigenomics; 2009 Oct; 1(1):63-79. PubMed ID: 22122637
[TBL] [Abstract][Full Text] [Related]
32. Snail maintains metastatic potential, cancer stem-like properties, and chemoresistance in mesenchymal mouse breast cancer TUBO‑P2J cells.
Ma SY; Park JH; Jung H; Ha SM; Kim Y; Park DH; Lee DH; Lee S; Chu IH; Jung SY; Kim IH; Choi IW; Choi CS; Park S
Oncol Rep; 2017 Sep; 38(3):1867-1876. PubMed ID: 28731185
[TBL] [Abstract][Full Text] [Related]
33. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells.
Preca BT; Bajdak K; Mock K; Sundararajan V; Pfannstiel J; Maurer J; Wellner U; Hopt UT; Brummer T; Brabletz S; Brabletz T; Stemmler MP
Int J Cancer; 2015 Dec; 137(11):2566-77. PubMed ID: 26077342
[TBL] [Abstract][Full Text] [Related]
34. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer.
Karousou E; Misra S; Ghatak S; Dobra K; Götte M; Vigetti D; Passi A; Karamanos NK; Skandalis SS
Matrix Biol; 2017 May; 59():3-22. PubMed ID: 27746219
[TBL] [Abstract][Full Text] [Related]
35. Identification of a subpopulation of long-term tumor-initiating cells in colon cancer.
Peng L; Xiong Y; Wang R; Xiang L; Zhou H; Gu H
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32729895
[TBL] [Abstract][Full Text] [Related]
36. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer.
Li J; Choi PS; Chaffer CL; Labella K; Hwang JH; Giacomelli AO; Kim JW; Ilic N; Doench JG; Ly SH; Dai C; Hagel K; Hong AL; Gjoerup O; Goel S; Ge JY; Root DE; Zhao JJ; Brooks AN; Weinberg RA; Hahn WC
Elife; 2018 Jul; 7():. PubMed ID: 30059005
[TBL] [Abstract][Full Text] [Related]
37. ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549.
Song Q; Sheng W; Zhang X; Jiao S; Li F
Tumour Biol; 2014 Feb; 35(2):1377-82. PubMed ID: 24072492
[TBL] [Abstract][Full Text] [Related]
38. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
39. RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing.
Maurin M; Ranjouri M; Megino-Luque C; Newberg JY; Du D; Martin K; Miner RE; Prater MS; Wee DKB; Centeno B; Pruett-Miller SM; Stewart P; Fleming JB; Yu X; Bravo-Cordero JJ; Guccione E; Black MA; Mann KM
Nat Commun; 2023 Dec; 14(1):8444. PubMed ID: 38114498
[TBL] [Abstract][Full Text] [Related]
40. Isoform switch of CD44 induces different chemotactic and tumorigenic ability in gallbladder cancer.
Miwa T; Nagata T; Kojima H; Sekine S; Okumura T
Int J Oncol; 2017 Sep; 51(3):771-780. PubMed ID: 28677740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
